Quoin Pharmaceuticals, Ltd.
SEC CIK 1671502 · QNRX · last insider filing 2026-03-31
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Sember Michael T | Director | filed 2023 - 2026 |
| Langer Dennis | Director | filed 2023 - 2026 |
| Cooper Joseph Patrick | Director | filed 2023 - 2026 |
| Culverwell Anthony James | Director | filed 2023 - 2026 |
| Carter Denise P. | Director · Chief Operating Officer | filed 2023 - 2026 |
| Leong Natalie Ee Mun | Director | filed 2023 - 2026 |
| Myers Michael | Director · Chief Executive Officer | filed 2023 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Lawlor Sally Bridget | Chief Financial Officer | filed 2025 - 2026 |
| Dunn Gordon | Chief Financial Officer | filed 2023 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.